美國(guó)Aegerion
Aegerion Pharmaceuticals aspires to change the way rare, genetic lipid disorders are treated. We are an emerging biopharmaceutical company focused on the development and commercialization of a novel life-altering therapeutic for debilitating and often fatal orphan diseases. The Company’s first product candidate in late-stage clinical development, lomitapide, is a small molecule, once-a-day, oral therapy to treat a severe form of hypercholesterolemia called HoFH.
如果您對(duì)本品感興趣請(qǐng)與我公司聯(lián)系
北京東方安諾生化科技有限公司
聯(lián)系電話(huà)：
手機(jī)：
：
QQ：
所有評(píng)論僅代表網(wǎng)友意見(jiàn)，與本站立場(chǎng)無(wú)關(guān)。